AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00905060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
Study NCT00905060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
Study NCT00905060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Resection
Description: Patients will undergo standard surgical resection of intracranial tumor
Study NCT03790293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
Study NCT03790293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids'therapy
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
Study NCT03790293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids'therapy
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
Study NCT03654586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.
Study NCT03654586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.
Study NCT03939221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infrared Lamp and Acupressure
Description: Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
Study NCT04124991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Radioembolization with Yttrium-90 Microspheres
Study NCT04124991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Radioembolization with Yttrium-90 Microspheres
Study NCT03195582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corsodyl
Description: following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
Study NCT02809638 — intervention group
Intervention type: OTHER
Intervention: ultrasound elastography
Study NCT03685279 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nurtured Heart Approach
Description: Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
Study NCT03685279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurtured Heart Approach
Description: Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
Study NCT03302533 — intervention group
Intervention type: PROCEDURE
Intervention: Total elbow arthroplasty
Description: Implantation of a total elbow arthroplasty after distal humerus fracture
Study NCT03699930 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal or sham tDCS will be applied to the scalp.
Study NCT03699930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal or sham tDCS will be applied to the scalp.
Study NCT02702934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
Study NCT02702934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
Study NCT01880515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
Study NCT02061761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified Dose on Specified Days
Study NCT02061761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: Specified Dose on Specified Days
Study NCT02839083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic Paravertebral group
Description: Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
Study NCT02839083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs II group
Description: Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
Study NCT00929305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia PL2000
Description: The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
Study NCT00929305 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Inactive laser light
Study NCT04542447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nuvastatic
Description: Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
Study NCT04542447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nuvastatic
Description: Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
Study NCT00597870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoluminal treament of thoracic lesions
Description: Endoluminal treament of thoracic lesions with a thoracic stent-graft
Study NCT04243161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission.
Study NCT04243161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission.
Study NCT01473420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Variable dose
Study NCT01473420 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epogen Amgen
Description: Variable dose
Study NCT06115577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: endometrial tissue and peripheral blood mononuclear cells receptivity
Description: Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam 20 MG/ML
Description: given by Oral route the dose of 20mg every 6 hours.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam (Acupan) 20 MG/ML Injectable Solution
Description: given by intravenous route at the dose of 20mg every 6 hours.
Study NCT03699930 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech and language therapy
Description: A trained speech pathologist will administer the speech and language therapy.
Study NCT03699930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech and language therapy
Description: A trained speech pathologist will administer the speech and language therapy.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, (paracetamol) 500Mg Tab
Description: 2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Acetaminophen paracetamol) IV Soln 10 MG/ML
Description: Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Piroxicam piroxan) 20 MG Oral Tablet
Description: 2 tablets of piroxicam (piroxan) administrated orally once per 24 hours.
Study NCT03626753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Piroxicam piroxan) 20Mg/1mL Injection
Description: 2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours.
Study NCT03688646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intensive Nutrition Intervention
Study NCT01904877 — intervention group
Intervention type: BEHAVIORAL
Intervention: Enhancing HIV testing
Description: SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
Study NCT02860468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
Study NCT02860468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
Study NCT00634543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/ Acetaminophen
Description: Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
Study NCT00634543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
Study NCT03851393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of cough with inhaled citric acid
Description: perform artificially induced cough by inhalation of citric acid at various strengths
Study NCT03851393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest™ analysis of saliva pepsin
Description: collect patient saliva for analysis of pepsin levels
Study NCT03851393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peptest™
Description: The Peptest™ lateral flow device
Study NCT03701165 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DryMouth Shield
Description: The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
Study NCT00077623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa or beta
Description: iv 3 times weekly, as prescribed
Study NCT00077623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta (Mircera)
Description: 60, 100 or 180 micrograms sc (starting dose) every 2 weeks
Study NCT00077623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta (Mircera)
Description: 60, 100 or 180 micrograms sc (starting dose) every 4 weeks
Study NCT03441191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
Study NCT03441191 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
Study NCT02286011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC (Mononuclear cells)
Description: The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device.
Study NCT02286011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo, 2ml of saline, will be infused like in the experimental arm.
Study NCT05468450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant
Description: Direct injection Foam sclerotherapy
Study NCT05468450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser Ablation (EVLA)
Description: EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
Study NCT03519308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
Study NCT03519308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
Study NCT03519308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
Study NCT03519308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
Study NCT01531218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
Study NCT01531218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04367337 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Study NCT04134104 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for Colorectal malignant diseases either LAR or APR
Description: Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
Study NCT03400670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator NCPAP
Description: infants will be randomized into two different NCPAP groups
Study NCT03717324 — intervention group
Intervention type: OTHER
Intervention: Procedure created in co-creation group
Description: Interventions will be those obtained from the co-creation workshop with patients
Study NCT00581711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Part Intervention
Description: A combination of training, an otitis media episode grouper, and clinical decision support.
Study NCT00581711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-Part Intervention
Description: A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
Study NCT00581711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-part intervention
Description: Provision of feedback on otitis media quality indicators
Study NCT01275261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing protocol to avoid Foley catheter placement
Description: A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
Study NCT03851679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: B-Type natriuretic peptide (BNP) serum values
Description: evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)
Study NCT03851679 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary echography
Description: Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)
Study NCT03851679 — intervention group
Intervention type: OTHER
Intervention: urine collection
Description: 6 hour and 24 hour urine collection after Cesarean Section
Study NCT02401256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study NCT02401256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study NCT02401256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.